Karyopharm Therapeutics reported $1.43M in Cost of Sales for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
TG Therapeutics TGTX:US 237K 27K
Abbott ABT:US $ 4987M 267M
Abbvie ABBV:US $ 4021M 259M
Amgen AMGN:US $ 1561M 157M
Astrazeneca AZN:US 2.28B 790M
AstraZeneca AZN:LN 2279M 790M
Biocryst Pharmaceuticals BCRX:US $ 0.24M 0.18M
Bristol Myers Squibb BMY:US $ 2471M 115M
Eli Lilly And LLY:US $ 2072.1M 21.9M
Epizyme EPZM:US $ 2.64M 516K
GlaxoSmithKline GSK:LN 3645M 30M
Johnson & Johnson JNJ:US $ 7598M 357M
Karyopharm Therapeutics KPTI:US $ 1.43M 684K
MacroGenics MGNX:US 48K 899K
Merk MRK:US $ 5334M 1507M
Nektar Therapeutics NKTR:US $ 5.32M 0.85M
Novartis NOVN:VX SF 3755M 245M
Novartis NVS:US $ 3755M 245M
Pfizer PFE:US $ 10010M 399M
Regeneron Pharmaceuticals REGN:US $ 404.9M 577.7M
Takeda 4502:JP Y 308380M 26976M
Ultragenyx Pharmaceutical RARE:US $ 6.1M 2.59M
YTE INCY:US $ 37.21M 1.36M